Back to top
more

Journey Medical (DERM)

(Delayed Data from NSDQ)

$7.53 USD

7.53
124,923

-0.38 (-4.80%)

Updated Aug 25, 2026 03:42 PM ET

After-Market: $7.51 -0.02 (-0.27%) 6:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (150 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

The Zacks Analyst Blog Highlights Beacon Roofing Supply, TopBuild, Journey Medical, and Shift4

by Zacks Equity Research

Beacon Roofing Supply, TopBuild, Journey Medical, and Shift4 are included in this Analyst Blog.

Zacks Equity Research

Journey Medical (DERM) Up on Update for Skin Disease Candidate

by Zacks Equity Research

Journey Medical (DERM) plans to submit a new drug application (NDA) to the FDA for DFD-29 to treat rosacea in adults by 2023-end. Stock rises.

Tirthankar Chakraborty headshot

4 Growth Stocks to Buy Ahead of a Strong Year-End Rally

by Tirthankar Chakraborty

With the Fed likely to trim interest rates along with seasonal tailwinds, growth stocks like Beacon Roofing Supply (BECN), TopBuild (BLD), Journey Medical (DERM) and Shift4 Payments (FOUR) are poised to gain strength.

Zacks Equity Research

Are You Looking for a Top Momentum Pick? Why Journey Medical Corporation (DERM) is a Great Choice

by Zacks Equity Research

Does Journey Medical Corporation (DERM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

What Makes Journey Medical Corporation (DERM) a Good Fit for 'Trend Investing'

by Zacks Equity Research

Journey Medical Corporation (DERM) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Corvus Pharmaceuticals (CRVS) and Journey Medical Corporation (DERM) have performed compared to their sector so far this year.

Zacks Equity Research

Journey Medical (DERM) & Maruho Ink Deal for Qbrexza Asia Rights

by Zacks Equity Research

Journey Medical (DERM) enters into a second licensing agreement with Maruho to develop and commercialize Qbrexza to treat hyperhidrosis in certain Asian countries. The stock surges 18.4%.

Zacks Equity Research

Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -35.29% and 15.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Assertio (ASRT) Q2 Earnings Miss Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -7.14% and 3.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

United Therapeutics (UTHR) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

United Therapeutics (UTHR) delivered earnings and revenue surprises of 18.82% and 12.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?